Comparative assessment of angiotensin ii type 1 receptor blockers in the treatment of acute myocardial infarction: Surmountable vs. insurmountable antagonist

Hae Chang Jeong, Myung Ho Jeong, Youngkeun Ahn, Shung Chull Chae, Seung Ho Hur, Taek Jong Hong, Young Jo Kim, In Whan Seong, Jei Keon Chae, Jay Young Rhew, In Ho Chae, Myeong Chan Cho, Jang Ho Bae, Seung Woon Rha, Chong Jin Kim, Donghoon Choi, Yang Soo Jang, Junghan Yoon, Wook Sung Chung, Jeong Gwan ChoKi Bae Seung, Seung Jung Park

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background The mechanisms of antagonism vary between the angiotensin II type 1 receptor blockers (ARBs): insurmountable antagonism and surmountable antagonism. Recent retrospective observational studies suggest that ARBs may not have equivalent benefits in various clinical situations. The aim of this study was to compare the effect of two categories of ARBs on the long-term clinical outcomes of patients with acute myocardial infarction (AMI). Methods We analyzed the large-scale, prospective, observational Korea Acute Myocardial Infarction Registry study, which enrolled 2740 AMI patients. They divided by the prescription of surmountable ARBs or insurmountable ARBs at discharge. Primary outcome was major adverse cardiac events (MACEs), defined as a composite of cardiac death, nonfatal MI, and re-percutaneous coronary intervention, coronary artery bypass graft surgery. Results In the overall population, the MACEs rate in 1 year was significantly higher in the surmountable ARB group (14.3% vs. 11.2%, p = 0.025), which was mainly due to increased cardiac death (3.3% vs. 1.9%, p = 0.031). Matching by propensity-score showed consistent results (MACEs rate: 14.9% vs. 11.4%, p = 0.037). In subgroup analysis, the insurmountable ARB treatment significantly reduced the incidence of MACEs in patients with left ventricular ejection fraction greater than 40%, with a low killip class, with ST segment elevation MI, and with normal renal function. Conclusions In our study, insurmountable ARBs were more effective on long-term clinical outcomes than surmountable ARBs in patients with AMI.

Original languageEnglish
Pages (from-to)291-297
Number of pages7
JournalInternational Journal of Cardiology
Volume170
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1

Keywords

  • Angiotensin
  • Myocardial infarction
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Comparative assessment of angiotensin ii type 1 receptor blockers in the treatment of acute myocardial infarction: Surmountable vs. insurmountable antagonist'. Together they form a unique fingerprint.

  • Cite this

    Jeong, H. C., Jeong, M. H., Ahn, Y., Chae, S. C., Hur, S. H., Hong, T. J., Kim, Y. J., Seong, I. W., Chae, J. K., Rhew, J. Y., Chae, I. H., Cho, M. C., Bae, J. H., Rha, S. W., Kim, C. J., Choi, D., Jang, Y. S., Yoon, J., Chung, W. S., ... Park, S. J. (2014). Comparative assessment of angiotensin ii type 1 receptor blockers in the treatment of acute myocardial infarction: Surmountable vs. insurmountable antagonist. International Journal of Cardiology, 170(3), 291-297. https://doi.org/10.1016/j.ijcard.2013.07.146